Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

Roche invests €200m in Munich biotech centre

Creates new jobs with expansion of German diagnostic production

UK Life Sciences Strategy - one year on

UK to introduce DNA mapping for cancer and rare diseases

Will sequence the genomes of up to 100,000 patients within five years

- PMLiVE

Eliquis meets targets as long-term VTE therapy

Pfizer and BMS report positive phase III data for the Factor Xa inhibitor

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

Stephen Whitehead appointed HCA president

ABPI head joins comms association as exec committee is reorganised

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

ABPI London offices

Biosimilars should be routinuely assessed by NICE, says ABPI

Calls for biosimilars to go through full HTA process

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links